These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 19478282

  • 1. High expression of gastrin-releasing peptide receptors in the vascular bed of urinary tract cancers: promising candidates for vascular targeting applications.
    Fleischmann A, Waser B, Reubi JC.
    Endocr Relat Cancer; 2009 Jun; 16(2):623-33. PubMed ID: 19478282
    [Abstract] [Full Text] [Related]

  • 2. Bombesin receptor subtypes in human cancers: detection with the universal radioligand (125)I-[D-TYR(6), beta-ALA(11), PHE(13), NLE(14)] bombesin(6-14).
    Reubi JC, Wenger S, Schmuckli-Maurer J, Schaer JC, Gugger M.
    Clin Cancer Res; 2002 Apr; 8(4):1139-46. PubMed ID: 11948125
    [Abstract] [Full Text] [Related]

  • 3. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation.
    Markwalder R, Reubi JC.
    Cancer Res; 1999 Mar 01; 59(5):1152-9. PubMed ID: 10070977
    [Abstract] [Full Text] [Related]

  • 4. Concomitant vascular GRP-receptor and VEGF-receptor expression in human tumors: molecular basis for dual targeting of tumoral vasculature.
    Reubi JC, Fleischmann A, Waser B, Rehmann R.
    Peptides; 2011 Jul 01; 32(7):1457-62. PubMed ID: 21605611
    [Abstract] [Full Text] [Related]

  • 5. Co-expressed peptide receptors in breast cancer as a molecular basis for in vivo multireceptor tumour targeting.
    Reubi C, Gugger M, Waser B.
    Eur J Nucl Med Mol Imaging; 2002 Jul 01; 29(7):855-62. PubMed ID: 12111125
    [Abstract] [Full Text] [Related]

  • 6. Androgen-dependent expression of the gastrin-releasing peptide receptor in human prostate tumor xenografts.
    de Visser M, van Weerden WM, de Ridder CM, Reneman S, Melis M, Krenning EP, de Jong M.
    J Nucl Med; 2007 Jan 01; 48(1):88-93. PubMed ID: 17204703
    [Abstract] [Full Text] [Related]

  • 7. Preclinical comparison of (111)In-labeled DTPA- or DOTA-bombesin analogs for receptor-targeted scintigraphy and radionuclide therapy.
    Breeman WA, de Jong M, Erion JL, Bugaj JE, Srinivasan A, Bernard BF, Kwekkeboom DJ, Visser TJ, Krenning EP.
    J Nucl Med; 2002 Dec 01; 43(12):1650-6. PubMed ID: 12468515
    [Abstract] [Full Text] [Related]

  • 8. Characterization of bombesin/gastrin-releasing peptide receptors in human breast cancer and their relationship to steroid receptor expression.
    Halmos G, Wittliff JL, Schally AV.
    Cancer Res; 1995 Jan 15; 55(2):280-7. PubMed ID: 7812958
    [Abstract] [Full Text] [Related]

  • 9. Species differences of bombesin analog interactions with GRP-R define the choice of animal models in the development of GRP-R-targeting drugs.
    Maina T, Nock BA, Zhang H, Nikolopoulou A, Waser B, Reubi JC, Maecke HR.
    J Nucl Med; 2005 May 15; 46(5):823-30. PubMed ID: 15872357
    [Abstract] [Full Text] [Related]

  • 10. Overexpression of gastrin-releasing peptide receptors in tumor-associated blood vessels of human ovarian neoplasms.
    Fleischmann A, Waser B, Reubi JC.
    Cell Oncol; 2007 May 15; 29(5):421-33. PubMed ID: 17726264
    [Abstract] [Full Text] [Related]

  • 11. Radiochemical investigations of [188Re(H2O)(CO)3-diaminopropionic acid-SSS-bombesin(7-14)NH2]: syntheses, radiolabeling and in vitro/in vivo GRP receptor targeting studies.
    Smith CJ, Sieckman GL, Owen NK, Hayes DL, Mazuru DG, Volkert WA, Hoffman TJ.
    Anticancer Res; 2003 May 15; 23(1A):63-70. PubMed ID: 12680195
    [Abstract] [Full Text] [Related]

  • 12. Effective inhibition of experimental human ovarian cancers with a targeted cytotoxic bombesin analogue AN-215.
    Engel JB, Keller G, Schally AV, Halmos G, Hammann B, Nagy A.
    Clin Cancer Res; 2005 Mar 15; 11(6):2408-15. PubMed ID: 15788692
    [Abstract] [Full Text] [Related]

  • 13. Nonconstitutive expression of the gastrin-releasing peptide autocrine growth system in human small cell lung carcinoma NCI-H345 cells.
    Aguayo SM, Miller Y, Boose D, Holley M, Portanova LB, Schuyler KD, Kane MA.
    Cell Growth Differ; 1996 May 15; 7(5):563-72. PubMed ID: 8732666
    [Abstract] [Full Text] [Related]

  • 14. 177Lu-AMBA: Synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer.
    Lantry LE, Cappelletti E, Maddalena ME, Fox JS, Feng W, Chen J, Thomas R, Eaton SM, Bogdan NJ, Arunachalam T, Reubi JC, Raju N, Metcalfe EC, Lattuada L, Linder KE, Swenson RE, Tweedle MF, Nunn AD.
    J Nucl Med; 2006 Jul 15; 47(7):1144-52. PubMed ID: 16818949
    [Abstract] [Full Text] [Related]

  • 15. Early over-expression of GRP receptors in prostatic carcinogenesis.
    Körner M, Waser B, Rehmann R, Reubi JC.
    Prostate; 2014 Feb 15; 74(2):217-24. PubMed ID: 24150752
    [Abstract] [Full Text] [Related]

  • 16. High affinity binding sites for gastrin releasing peptide on human gastric cancer and Ménétrier's mucosa.
    Preston SR, Woodhouse LF, Jones-Blackett S, Wyatt JI, Primrose JN.
    Cancer Res; 1993 Nov 01; 53(21):5090-2. PubMed ID: 8221641
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast.
    Gugger M, Reubi JC.
    Am J Pathol; 1999 Dec 01; 155(6):2067-76. PubMed ID: 10595936
    [Abstract] [Full Text] [Related]

  • 19. Gastrin-releasing peptide receptors in normal and neoplastic human uterus: involvement of multiple tissue compartments.
    Fleischmann A, Waser B, Gebbers JO, Reubi JC.
    J Clin Endocrinol Metab; 2005 Aug 01; 90(8):4722-9. PubMed ID: 15941862
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.